Gentile sponsors resolution for diabetes funding

Staff Report

COLUMBUS — Ohio Sen. Lou Gentile (D-Steubenville) offered Wednesday to sponsor testimony, with Sen. Troy Balderson (R-Zanesville), the state Senate Health and Human Services Committee for the bipartisan Senate Concurrent Resolution 2.

Senate Concurrent Resolution 2 (SCR 2) would call on the U.S. Congress to increase federal funding for research and development involving advanced medical technology used in the treatment of Type I diabetes. This chronic condition, also known as juvenile diabetes, occurs when the pancreas produces little or no insulin. Insulin is needed in order for glucose to enter the cells to produce energy.

“Providing enough funding for research and development in new medical breakthroughs could dramatically improve the quality of life for those living with the disease and for their families,” Gentile said. “Increased funding for diabetes research could potentially save billions of taxpayer dollars in health care costs and lead to better health outcomes for millions of people.”

Adequate federal funding for research, especially research involving a closed-loop insulin delivery system, is needed for realistic pathways to a cure for Type 1 diabetes. Currently, the disease has no cure and affects more than 1 million Americans. Allowing more access to new medical technologies for patients of this disease could save billions in health care costs and lost productivity, Gentile said.

This resolution is supported by the Juvenile Diabetes Research Foundation.

Staff Report